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Abstract
Objective: This study investigated the officially registered and controlled 
HIV cases in Bahrain over the last 10-year period. Starting in 2011, a 
multidisciplinary team was established for HIV management involving 
major stakeholders; public health, infectious diseases, pharmacists, 
nursing and virologists.
Methods: A retrospective descriptive study is done about all HIV 
positive patients in Bahrain. Data was collected retrospectively from 
the 2014 registry for HIV patients, and their ART regimen, CD 4 count 
and viral load were obtained and entered in Excel sheet.
Results: A total of 208 patients were diagnosed to have HIV up to 2014. 
However, only 108 of them have all necessary data to be included in 
the study. In addition, a review of the frequency of admission of these 
patients over a 10-year period was performed. Review the medical 
records of the patients, indicated that the total of death among HIV 
positive patients were 38 (35.6%) over the study period. Hepatitis 
C was the most common co-infection observed among 26 patients 
(24%), followed by tuberculosis with 24 patients (22.2%).
Conclusion: It was found that usage of ART treatment regimen of 
efavirenz , darunavir and lopinavir, better structure of HIV team 
and program, had helped to control better the patients, and there 
was a clear increase in the number of patients with improving CD4 
count. Based on the results of this study, the HIV multi-disciplinary 
management team is found an essential part for the best management 
of these patients.
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Introduction 
Human immunodeficiency virus (HIV) is a lenti-
virus which is a subgroup of retrovirus that causes 
acquired immunodeficiency syndrome (AIDS) and 
predispose for opportunistic infections and malig-
nancies. HIV infects certain cells in the immune sys-
tem such as helper T cells (CD 4 T cells in particu-
lar), macrophages and dendritic cells. Many of the 
individuals who are HIV-positive can be unaware 
of their infection [1]. According to global studies in 
2012, it is estimated that 35.5 million people were 
living with the virus. Of these, 2.1 million were 
adolescents aged between 10-19 years, of which 
the girls accounted to 56% [2]. The majority of HIV 
infections in the sub-Saharan Africa were adoles-
cents . Outside Africa, South Asia had the highest 
number of HIV positive adolescents, estimated to be 
6% of the global burden. These were followed by 
East Asia and Pacific (110.000), Latin America and 
the Caribbean (81.000), Eastern Europe and Central 
Asia (22,000) and the middle East and North Africa 
(17,000) [3]. 
In 2013, 1.5 million people died of AIDS, a 35% 
decrease since 2005. The number of deaths has 
decreased in part due to available of antiretroviral 
treatment (ART). Multiple prevention strategies exist 
to combat the virus including recommending cir-
cumcision, use of condoms, behavior changes, and 
blood supple safety. On the other hand, HIV treat-
ment includes both ART and other medication to 
prevent and treat opportunistic infections. Globally, 
it is estimated that 37% of people living with HIV 
are getting treatment and around 75% of all people 
receiving antiretroviral therapy live in sub-Saharan 
Africa [4].The publication and the availability of data 
about the epidemiology of HIV in the middle-east 
region is very limited. Our research provides some 
of these data about the kingdom of Bahrain. 
In the Kingdom of Bahrain, screening for HIV sta-
tus started in 1989. The HIV positive patients have a 
registry in the public health sector of the Ministry of 
Health. The patients get a regular medical follow-up 
for their health status via outpatient clinic appoint-
ments. A retrospective descriptive study is done 
about those patients, their current treatment regi-
mens and other blood parameters aiming to have 
a general idea about their health status in order to 
help in their medical care. 
Methods and Materials 
In Bahrain, a multidisciplinary team was estab-
lished in 2011, for HIV management involving ma-
jor stakeholders: public health, infectious diseases, 
pharmacists, nursing and virologists. The team es-
tablished a system which capture each step of pa-
tients care to improve its quality. This team meets 
regularly, puta a complete action plan to form an 
integrated system to provide the best care for these 
patients. 
We started collecting the basic data which in-
volved the followings: 
First form: The demographic information about 
the patients, their risk factors, their progress and 
Table 1.  Demographic characteristics of HIV 
examined patients 
Items* No.(%)
Total no. of registered patients 108(100)
Total no. of admitted patients to regular 
treatment
95(87.9 )
Males 73(67.6 )
Females 22 (20.4 )
Recurrent 3 admissions 23 (21.5 )
The average age of admitted cases 37-year
CD4 count less than200ug/dl 23(21.3)
CD4 count between200-500ug/dl 31( 28.7)
CD4 count more than 38 (35.19)
*38/76 (50%) had detectable viral load
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response to treatment and their follow up, their 
prevention protocol. 
The second form include the serial of their blood 
tests specifically, HIV viral load, CD4 count and the 
genotyping.
Third form: Lists from the pharmacy where we 
assigned one pharmacist to look after these pa-
tients, where we get an updated list of the patients 
with their medications , and if they missed taking 
them to call them urgently to ensure compliance. 
We assigned a nurse coordinator for the HIV 
service who overlooks the whole process of data 
collection, entering and providing patient support 
services 
These data were entered in a soft copy excel 
sheets to analysis the data. Over the same period 
we introduced new and updated HIV medications 
to increase the response rate to HIV medications.
A software database was established to include 
all patients: to record their visits, labs results, clinical 
progress, medications regimen and their appoint-
ments to flag missed ones.
The data was collected retrospectively from the 
current created registry about all patients who are 
currently living with HIV and are followed in the 
same hospital. This hospital is a secondary and ter-
tiary care hospital and the only hospital in the king-
dom of Bahrain that provide care for HIV patients. 
Their ART regimen, CD 4 count and viral load were 
gathered and entered in Excel sheet. In addition, a 
review of the frequency and reason of admission, 
the most common infections and the mortality rate 
for all cases of HIV that were admitted to the same 
hospital over a 10 year period. The information was 
collected during the period 2004 to 2014 from the 
medical records of patients. All data including their 
names were dealt with in complete privacy. All pa-
tients were included without any exclusion criteria. 
Results 
A total of 208 patients were diagnosed to have 
HIV and many of them are still alive up to 2014. 
However, only 108 of them have their full data (in-
cluding house address and contact details) docu-
mented. The rest of them have no trace. Of those 
108 patients with full data and regular clinic follow 
up, only 95 are on regular treatment. The other 13 
patients are not attending their outpatient HIV clinic 
appointments. Out of the 95 patients, 73 are males 
and 22 are females. 
In addition, the medical records of all HIV pa-
tients who were admitted over the last ten years 
from 2004 till 2014, it was found that the total 
admission of HIV positive patients were 108. Of 
those, 23 had recurrent admissions with an aver-
age number of three admissions per patient. The 
average age of admitted cases was 37 years. 
Hepatitis C was the most common co-infection 
among those patients and accounted to 24%. It 
was followed by Hepatitis B with 3.73% , and only 
3% had double infection with both types of viruses 
(B and C). 
The CD4 count was done to the patients upon 
diagnosis of the virus which varied in year from 
one to another and repeated thereafter as man-
dated by the patients’ condition. According to the 
first CD4 count it showed that 26 out of the 95 
patients had a count of less than 200ug/dl, 36 had 
count between 200-500ug/dl and 30 were more 
than 500ug/dl. Three patients had no CD4 counts 
due to laboratory error [Figure 3]. The repeated 
CD4 count showed 23 with count less than 200ug/
dl, 31 with count between 200-500ug/dl and 38 
with CD4 more than 500ug/dl. For one patient it 
was not repeated since diagnosis and two other 
the sample was not processed by the laboratory 
due to uncertain error [Table 2]. The CD4 count 
was repeated on average two to three years after 
the patients’ first collected sample and initiating 
his treatment. 
The viral load was done to 76 of the patients 
on treatment and it showed that 38/76 (50%) had 
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detectable viral load, target not detected in 38/76 
(50%) from the total patients who had viral load 
done and 40% form the total number of patients 
who are currently on treatment. 
A total of 95 patients were on different medica-
tion regimens. Of these, 49(51.6 %) were on efavi-
renz based regimen and 31 (32.6%) (n=31) were on 
darunavir based regimen and 15 on lopinavir based 
regimen (15.7%) as shown in Table 3. 
Thirteen out of the 107 patients presented with 
respiratory symptoms such as shortness of breath 
and cough or vague symptoms like fever and were 
admitted and managed as pneumonia without iso-
lating a specific organism. On the other hand, 21 
patients were diagnosed to have respiratory Tuber-
culosis (TB), three with military TB and two with 
recurrent TB due to drug non-compliance upon 
discharge at the first admission. One case had TB 
lymphadenitis [Table 2]. Their diagnosis was con-
firmed using AFB of sputum and bronchial wash or 
PCR for detection AFA , in addition to the clinical 
picture. Twelve patients were admitted with sus-
pected sepsis without proving the agent of infection. 
Others had various reasons for admission such as 
drug overdose, myocardial infarction, alcohol intoxi-
cation and gastrointestinal bleed. Regarding central 
nervous system infections, one diagnosed with viral 
encephalitis, three cases with cryptococcal menin-
gitis and two patients with toxoplasma encephali-
tis. The mode of presentation varied. Nonetheless, 
oral candidasis was a common coincidental finding 
in many patients. One patient was diagnosed with 
Kaposi sarcoma after presenting with violacous skin 
lesions where a biopsy was taken. 
Fourteen patients had positive deep tracheal 
aspirate(DTA) / sputum. The organisms grown were 
various such as S aureus, Pseudomonas spp., and 
E.coli and multi-drug resistant Acintobacter spp. 
Some DTA cultures have grown multiple organisms 
[Table 4] .
Discussion 
There has been significant scale-up of the use of 
Table 2.  Treatment regimen of the 95 HIV 
patients
Drug combination No. (%) 
Efavirenz based regimen 49(51.6)
Darunavir based regimen 31(32.6)
Lopinavir based regimen 15 (15.7)
Table 4.  Profile of bacteria isolates from sputum /
DTA and associated with respiratory tract 
infections among HIV patients
Organism Type* Sensitivity No.
Staph aureus Highly susceptible** 2
E.coli (ESBL) Susceptible only to Carbapenems 3
Methicillin 
resistant S. aureus
Susceptible only to Vancomycin 1
E. coli Highly susceptible 1
Pseudomonas 
spp.
Highly susceptible 2
Acintobacter spp. 
(MDR)
Susceptible to colistin/ tegicycline 3
Klebsiella spp.
(ESBL-producer)
Susceptible only to Carbapenems 2
Klebsiella spp. Highly susceptible 3
*Some culture specimens grew more than one bacteria spp. 
**To most tested antibiotics
Table 3.  Major microbial infections observed 
among 108 HIV Patients
Microbial infections No. (%)
Hepatitis C 26 (24)
Hepatitis B 4 (3.7)
Hepatitis C & Hepatitis B 3 (3)
Pulmonary tuberculosis 21 (19.6)
Extra-pulmonary tuberculosois 4 (3.7)
Cryptococcal meningitis 3 (2.8)
Toxoplasma encephalitis 2 (1.9)
Kaposi sarcoma 1 (0.9)
Candidasis Null
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ART especially with the increase incidence of HIV 
positive patients. However, drug compliance is the 
cornerstone in the successful of HIV infection man-
agement. The success of any treatment plan relies 
on life-long, high degree of medication adherence 
to have the best clinical outcome and reduce the in-
cidence of drug resistance. Reviews of over 50 years 
of research studies have shown that drug compli-
ance rates above 80% for treating various chronic 
illnesses has been a serious issue even in well devel-
oped rich countries. Therefore achieving good rates 
of medication compliance in under developed poor 
resource countries is a big challenge and must be 
closely monitored [5]. Our review showed a CD4 
count response among the patient over the years 
which indicate good drug compliance by them. It is 
highly important for HIV patients to be admitted for 
continuous clinic visit, regular laboratory tests and 
medication adherence [6]. 
According to recent reports from Middle East 
and Middle East region (MENA), 60% of HIV infec-
tions among women occur before the age of 20 
and the more than 50% of the new infection are 
seen in the 15-24 age groups [7]. It was found that 
of the nearly 500,000 infected individuals with HIV 
in the region; almost half of them are females. In 
addition, sexual transmission of HIV is increasing in 
the region. Married women in particular are among 
the most vulnerable to HIV infection due to the fact 
that they do not see themselves as being so because 
of social structure and customs that surrounds them 
[8]. Actually these customs do not only surround 
women but it prevails men too. For example, young 
men are assumed not to be sexually active until they 
are married and married men are faithful to their 
wives with no extra-marital relations. However, the 
prevalence of sexually transmitted disease is fairly 
high in some regions according to certain studies 
that indicate much extra-marital unprotected sexual 
relations [9].Therefore, thorough history from all pa-
tients despite their background is advised for early 
detection of new cases which will influence their 
diagnosis, management and transmission to other 
partners. 
Proper understanding of the accurate HIV epi-
demic in MENA region has been sluggish due to 
problems inherent to low HIV prevalence in the 
population compared to other population. In ad-
dition, the pace of the development of surveillance 
systems is slow with insufficient data collection and 
analysis[10]. Despite the number of people living 
with HIV in the MENA countries has increased over 
the last decade, the current prevalence of 0.1% is 
still among the lowest rates worldwide. Five coun-
tries including Algeria, Islamic Republic of Iran, Mo-
rocco, Somalia, and Sudan accounted for 88% of 
these people living with HIV infection [11]. 
The stigma and discrimination behind the people 
living with HIV is a major factor in the MENA region 
that creates difficulty in approaching hidden popula-
tion with positive HIV. The moral views towards the 
HIV positive people in most Arab/ Muslim countries 
both in the community and the health system is a 
major obstacle for patients to seek care and treat-
ment. In a study done in Egypt included 153 HIV 
positive patients showed 51.6% feeling stigmatized 
by others in the community and 43.1% reported 
changes in people’s views towards them. In addi-
tion, 66.7% isolated themselves from the communi-
ty because fear of disgrace, 44.4% noticed changes 
in the behaviors of their relatives and 53.6% felt 
useless to their community [12].
Based on our study results, we found that with 
better ART treatment and better structure of HIV 
team and program, we are getting more patients to 
be controlled. There is a clear increase in the num-
ber of patients with improving CD4 count. There 
is also a higher number of patients with undetect-
able viral load. Reports showed that ART lowers the 
HIV transmission possibility and as the ART coverage 
rate increases, HIV incidence decreases. ART is rec-
ommended in all HIV positive cases despite their CD 
4 count which is termed “Treatment as prevention” 
The rate of ART coverage has increased in the re-
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gion during the last decade. However, by the end of 
2013, the ART coverage in the region was still lower 
compared to countries in other regions through-
out the world. The coverage was estimated to be 
around only 11%. Despite significant efforts made 
by all countries in the region to increase the num-
ber of people receiving treatment, the fast growing 
number of new HIV cases is a major obstacle to 
close the gap. In 2013, less than one out of eight 
positive patients living with the virus eligible for ART 
received it in Djibouti, Iran, Egypt, Somalia, Sudan, 
and Yemen. As a result, the region has experienced 
a significant increase in mortality due to AIDS which 
has reached 17% in 2012. [13]
The high rate of hepatitis C co-infection is be-
cause that the majority of HIV patients are IV drug 
users. Drug addiction is a persistent and growing 
problem in MENA. According to the United Nations 
Office on Drugs and Crime, 83% of the world sup-
ply of heroin is produced in Afghanistan, and >75% 
of this is marketed through Iran. The number of 
injecting drug abusers in MENA is estimated to be 
335, 000–1, 635 000. Drug abuse was the most 
common mode of HIV transmission among men 
in Iran (73.5%) and Afghanistan (60.2%) in 2011. 
While Iran has had the highest numbers of positive 
HIV patients among all countries in the region (185 
000), it is followed by Pakistan (117 000) and Egypt 
(89 000), where injecting drug use contributed to 
20% and 23%, respectively, of all newly notified 
cases in 2011; and the lowest number (1000) was 
reported in Somalia. [14] 
Opportunistic infections are commonly observed 
in HIV patients who have limited medical care or a 
consequence of medication with non compliance / 
virus resistance to ART. A retrospective study con-
ducted in Bahrain between the period of 2009-2013 
that aimed to examine the prevalence of opportunis-
tic infections and its relation to absolute CD4 count 
(CD4 % and CD4/CD8) ratio. The results showed 
CD4% and absolute CD4 count in HIV patients with 
associated infection was significantly lower than in 
those without evidence of opportunistic infections 
(157 ± 295 and 471 ± 285, respectively) with p < 
0.001. The most common opportunistic infections 
AIDS patients were due to Staphylococcus aureus 
followed by yeast infections (28.7% and 27.2%, 
respectively). PCP was present in 15.1%, Mycobac-
terium Tuberculosis and Mycobacterium other than 
tuberculosis in 10.6% and 7.5% respectively in op-
portunistic infections group patients [15]. Our report 
roughly investigated the frequency of infections in 
HIV and AIDS group patients without segregation. 
The majority had symptoms and signs indicating 
an infection, however, many of them were treated 
empirically without isolating the causative organ-
ism. This could be due to defect in collecting the 
proper samples or delay in the collection specimens 
for septic work-up. For those who have a significant 
isolated organism, Mycobacterium tuberculosis was 
the leading cause of infection either in respiratory 
tract or extra-pulmonary site.  
Conclusion 
Based on the results of this study, the HIV multi-
disciplinary management team is an essential part 
for the best management of HIV patients. This ap-
proach will also decreases developing opportunistic 
infections. Education about the disease should be 
encouraged in the society. Equally important is sur-
veillance among the high risk groups (sex workers 
and drug abusers) for early detection of infected 
individuals. The social stigmata of having the virus 
are a main concern among those patients which 
prohibits many of them to approach medical care 
and receive the proper treatment. 
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